ProShare Advisors LLC Purchases 6,606 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

ProShare Advisors LLC increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 41.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,646 shares of the medical equipment provider's stock after buying an additional 6,606 shares during the quarter. ProShare Advisors LLC's holdings in Lantheus were worth $2,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Kestra Investment Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at about $27,000. Summit Securities Group LLC acquired a new stake in Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. raised its holdings in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. acquired a new position in shares of Lantheus in the 4th quarter worth approximately $125,000. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $0.89 during trading on Monday, hitting $73.86. The stock had a trading volume of 671,503 shares, compared to its average volume of 988,498. The firm has a fifty day moving average of $94.56 and a two-hundred day moving average of $92.11. The company has a market capitalization of $5.11 billion, a PE ratio of 12.29 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.69 EPS. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.